Shared decision making
More people living with HIV would be interested in trying long-acting injectable ART than physicians assume
The Spanish CoRIS cohort highlighted a gap between interest in long-acting injectable therapy from people living with HIV and physicians’ perception of treatment preference.[1]
When physicians were asked…
People living with HIV said...
Discover the power of choice through the VOLITION study data
Global consensus recommendations* state that eligible people living with HIV should be informed about the option of long-acting ART, with shared decision making to determine if it is an appropriate choice for them.[2]
Shared decision making
In a cross-sectional study of patient-provider communication across 25 countries:†[3]
High engagement between physicians and people living with HIV was associated with significantly better reported health outcomes for people living with HIV, such as patient-reported optimal physical and mental health when compared to regular daily orals
Increasing people living with HIV’s engagement in treatment decision making was significantly associated with better indicators of quality of life when compared to regular daily orals
*Global consensus recommendations were endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society and Society of Infectious
Diseases Pharmacists.[2]
†Analysis of 2,389 adults on ART from across 25 countries (Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russia, South Africa, South Korea, Spain, Switzerland, Taiwan, United Kingdom and United States), in the Positive Perspectives 2 study.[3]
Discover our resources about long-acting injectable treatment, including a shared decision making tool:
AIDS=acquired immunodeficiency syndrome; ART=antiretroviral therapy; ARV=antiretroviral; HIV=human immunodeficiency virus.
References:
- Moreno C, Izquierdo R, Alejos B, et al. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain. AIDS Patient Care STDS. 2024;38(7):305–314. doi: 10.1089/apc.2024.0093.
- Sherman EM, Agwu AL, Ambrosioni J, et al. Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2024;44(7):488–493. doi: 10.1002/phar.2921.
- Okoli C, Brough G, Allan B, et al. Shared Decision Making Between Patients and Healthcare Providers and its Association with Favorable Health Outcomes Among People Living with HIV. AIDS Behav. 2021;25(5):1384-1395. doi: 10.1007/s10461-020-02973-4.
REKAMBYS (rilpivirine long-acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned or licensed by the ViiV Healthcare group. ©2025 ViiV Healthcare group of companies or its licensor. All rights reserved.
PM-GB-CBR-WCNT-250009 | March 2026
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
